Ten-Year Experience of Rhinocerebral Zygomycosis in a Teaching Hospital in Tehran

Author(s):
Mitra BaratiMitra Barati1,*, Marzieh NojomiMarzieh Nojomi2, Fatemeh KeramiFatemeh Kerami1
1Pediatric Infectious Diseases Research Center, Iran University of Medical Sciences, Tehran, IR Iran
2Department of Community Medicine, Iran University of Medical Sciences, Tehran, IR Iran
*Corresponding Author: Pediatric Infectious Diseases Research Center, Iran University of Medical Sciences, Tehran, Iran., [email protected]. Email: [email protected]

Archives of Clinical Infectious Diseases:Vol. 5, issue 3; 117-120
Published online:Jul 31, 2010
Article type:Research Article
How to Cite:Barati M, Nojomi M, Kerami F. Ten-Year Experience of Rhinocerebral Zygomycosis in a Teaching Hospital in Tehran. Arch Clin Infect Dis. 2010;5(3):. doi:

Abstract

Background:

Rhinocerebral zygomycosis is a rare, rapidly progressive and often fatal fungal infection occurring in several immunocompromised states. Prior investigators have reported an increasing incidence among Iranian population; therefore, we decided to present the clinical features and treatment outcome of a group of patients with rhinocerebral zygomycosis.

Patients and Methods:

Medical records of all cases with the diagnosis of rhinocerebral zygomycosis attending Rasoule- Akram Hospital, Tehran, Iran, were retrospectively reviewed from 1997 to 2007. Age, gender, predisposing illness, surgical procedures, and treatment outcomes were reviewed.

Results:

Totally, 30 patients (17 males and 13 females) were reviewed with a mean age of 49.420.3 years. The lag time between onset of symptoms referable to zygomycosis and commencement of amphotericin B was 1 to 90 days with median of 10 days. An association between delayed treatment and mortality was found (p=0.01). Visual loss was observed in 53.3%. The ethmoid (86.6%) and maxillary sinuses (66.6%) were most commonly involved. Eighteen patients had underlying diabetes mellitus (60%). All patients received medical treatment, while 28 (93.3%) underwent surgical intervention. Twenty three patients (76.7%) had orbital involvement with a mortality rate of 43.5%. The overall mortality rate was 40% (12 cases). Patients with higher doses of amphotericin B and multiple surgical intervention had lower mortality rate (p=0.00 and p=0.01, respectively). Factors such as age, gender, predisposing diseases, orbital involvement, multi-sinus involvement, and white blood cell count had no impact on survival rate.

Conclusion:

Institution of aggressive surgical debridement of devitalized tissue and the timely initiation of systemic medical therapy is critical for good outcome.

Full Text

Full text is available in PDF

Copyright

© 2010, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.

Similar Articles

30
Oct
2024
Arch Clin Infect Dis

Improving the Outcome of Patients Diagnosed with Rhino-orbito-cerebral Mucormycosis in the Last Two Decades: 97 Patients in Two Referral Centers in the Northeast of Iran

Mahnaz Arian,
Sarina Aeen,
Amin Bojdi,
Mehdi Jabbari Nooghabi,
Ali Tajik,
Marzieh Baghoveh
,et al.

Arian M, Aeen S, Bojdi A, Jabbari Nooghabi M, Tajik A, et al. Improving the Outcome of Patients Diagnosed with Rhino-orbito-cerebral Mucormycosis in the Last Two Decades: 97 Patients in Two Referral Centers in the Northeast of Iran. Arch Clin Infect Dis. 2024;19(5):e151510. doi: https://doi.org/10.5812/archcid-151510

9
Oct
2016

Epidemiology and Treatment Outcome of Mucormycosis in Khuzestan, Southwest of Iran

Roohangiz Nashibi,
Sara Afzalzadeh,
Mohammad Javad Mohammadi,
Ahmad Reza Yari,
Farid Yousefi

Nashibi R, Afzalzadeh S, Mohammadi MJ, Yari AR, Yousefi F. Epidemiology and Treatment Outcome of Mucormycosis in Khuzestan, Southwest of Iran. Arch Clin Infect Dis. 2017;12(1):e37221. doi: https://doi.org/10.5812/archcid.37221

9
Mar
2019
69100

Molecular Identification of Causative Agents in 25 Cases with Mucormycosis in Iran

Mahsa Naeimi Eshkaleti,
Seyed Jamal Hashemi,
Mehraban Falahati,
Shahram Mahmoudi,
Farideh Zaini,
Hossein Mirhendi
,et al.

Naeimi Eshkaleti M, Hashemi SJ, Falahati M, Mahmoudi S, Zaini F, et al. Molecular Identification of Causative Agents in 25 Cases with Mucormycosis in Iran. Arch Clin Infect Dis. 2019;14(1):e69100. doi: https://doi.org/10.5812/archcid.69100

23
Jan
2016

Combination Antifungal Treatment for Sino-Orbito-Cerebral Mucormycosis: A Case Report

Masoud Mardani,
Davood Yadegarynia,
Shabnam Tehrani

Mardani M, Yadegarynia D, Tehrani S. Combination Antifungal Treatment for Sino-Orbito-Cerebral Mucormycosis: A Case Report. Arch Clin Infect Dis. 2016;11(1):e28345. doi: https://doi.org/10.5812/archcid.28345

30
Apr
2017

Otomycosis in Western Iran: Clinical and Mycological Aspects

Sajad Cheraghsahar,
Siros Kazemi,
Mehdi Birjandi,
Mohammad Yarahmadi,
Shahram Mahmoudi,
Rasoul Mohammadi
,et al.

Cheraghsahar S, Kazemi S, Birjandi M, Yarahmadi M, Mahmoudi S, et al. Otomycosis in Western Iran: Clinical and Mycological Aspects. Arch Clin Infect Dis. 2017;12(2):e57287. doi: https://doi.org/10.5812/archcid.57287

Download PDF46.59 KB
Share on
Cited by
Metrics

Ordering Reprints

Articles are published under the Creative Commons license stated on each article. No permission or royalty fee is required for uses permitted by that license. CCC handles optional bulk and customized reprint orders. Any quotation covers production and delivery services only, not copyright permission. > Request Reprints from CCC 

Search Relations

Author(s):

Related Articles